Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spyre TherapeuticsSYRE +10.54%26 EV-to-EBITDA is -35.29 as of Aug. 05, 2026. GuruFocus rates SYRE with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 411 Biotechnology companies, Spyre Therapeutics ranks worse than 243308.76% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Spyre Therapeutics's enterprise value is $8,527.48 Mil.
Spyre Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-241.64 Mil. Therefore, Spyre Therapeutics's EV-to-EBITDA for today is -35.29.
The historical rank and industry rank for Spyre Therapeutics's EV-to-EBITDA or its related term are showing as below:
SYRE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -35.29 Med: -1.9 Max: 2.25
Current: -35.29
During the past 13 years, the highest EV-to-EBITDA of Spyre Therapeutics was 2.25. The lowest was -35.29. And the median was -1.90.
SYRE's EV-to-EBITDA is ranked worse than 100% of 411
companies
in the Biotechnology industry
Industry Median: 12.78
vs SYRE: -35.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Spyre Therapeutics's PE Ratio (TTM) for today is calculated as:
Spyre Therapeutics's share price for today is $105.00.
Spyre Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.229.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Spyre Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Spyre Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's EV-to-EBITDA falls into.
Spyre Therapeutics's current Enterprise Value is $8,527.48 Mil.
Spyre Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-241.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics (SYRE) has a EV-to-EBITDA of -35.29 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Spyre Therapeutics. According to the industry distribution chart, Spyre Therapeutics ranks #999999 out of 411 companies in the Biotechnology industry.
Is Spyre Therapeutics' EV-to-EBITDA too high?
Spyre Therapeutics' current EV-to-EBITDA is -35.29. Based on the distribution chart, Spyre Therapeutics ranks #999999 out of 411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' EV-to-EBITDA compare to CRNX and PTGX?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #999999 out of 411 companies for EV-to-EBITDA. This places Spyre Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 12.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.78, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Spyre Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current EV-to-EBITDA is -35.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (SYRE) has a current EV-to-EBITDA of -35.29. The current EV-to-EBITDA is -35.29. Spyre Therapeutics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Spyre Therapeutics (SYRE), the current EV-to-EBITDA is -35.29 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
26GF Score
Get the complete analysis for SYRE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYRE has been successfully added to your 
